Investors & Media

News

  • Item Type:
  • Year:
  • 9 Jan. 2012

    Kamada receives emphysema treatment patent approval

    The drug developer received approval for its AAT (Alpha-1 Antitrypsin) drug that treats chronic emphysema due to congenital deficiency.

  • 2 Aug. 2011

    Kamada obtains FDA orphan drug status for diabetes treatment

    In June, Kamada began a Phase I/II clinical trial of D1-AAT treatment at two medical centers in Israel. The company expects to publish interim results in early 2012, and the final reports later in the year.

  • 11 Jun. 2011

    Kamada begins Phase I/II juvenile diabetes trial

    The Israeli Ministry of Health has approved the trial protocol to test the safety profile and efficacy of the drug for this indication. The trial will be conducted at two Israeli medical centers by Contract Research Organization under an agreement with Kamada.

  • 8 Mar. 2011

    Kamada Receives an Israeli Patent for its Ultrapure Transferrin for Pharmaceutical Compositions

    This is the second patent issued to Kamada under the same title after being granted with the same patent title by the United States Patent Office (USPTO).

  • 27 Oct. 2010

    Baxter announces launch of GLASSIA in the U.S.

    Baxter International Inc. (NYSE: BAX) today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.